Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Feb;59(2):202-6.
doi: 10.1136/jcp.2005.028480.

Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours

P Kornprat  1 , P Rehak, J Rüschoff, C Langner
Affiliations

Expression of IGF-I, IGF-II, and IGF-IR in gallbladder carcinoma. A systematic analysis including primary and corresponding metastatic tumours

P Kornprat et al. J Clin Pathol. 2006 Feb.

Abstract

Aims: The insulin-like growth factor (IGF) system has been implicated in tumour development and progression. This study was designed to analyse the expression of the IGF-I receptor (IGF-IR) and its ligands (IGF-I, IGF-II) in gallbladder cancer.

Methods: IGF-I, IGF-II, and IGF-IR immunoreactivity was investigated in 57 gallbladder carcinomas and corresponding lymph node (n = 11) and hepatic (n = 7) metastases using a tissue microarray technique and correlated with tumour stage, grade, and patient outcome.

Results: Cancer tissue allowing a reliable evaluation of IGF-I, IGF-II, and IGF-IR was present in 55 of 57 primary tumours and 17 of 18 metastases. IGF-I and IGF-II immunoreactivity was seen in 25 and 14 of the 55 primary tumours, in addition to six and three of the 17 metastases, respectively. No associations with tumour stage, grade, or prognosis were detected. IGF-IR was expressed in 52 of 55 primary tumours and all 17 metastases. IGF-IR staining intensity decreased with tumour cell dedifferentiation. Moreover, IGF-IR expression in less than 50% of cancer cells was an independent marker of poor prognosis in multivariate analysis (risk ratio, 4.0; 95% confidence interval, 1.4 to 11.2; p = 0.01).

Conclusions: The expression of IGF-IR and its ligands provides evidence for the existence of an auto/paracrine loop of tumour cell stimulation in gallbladder cancer and makes this type of cancer a candidate for therapeutic strategies aimed at interfering with the IGF pathway. The recognition of IGF-IR as a new independent prognostic biomarker may help to identify patients who might benefit from adjuvant treatment.

PubMed Disclaimer

References

    1. Misra S, Chaturvedi A, Misra N C.et al Carcinoma of the gallbladder. Lancet Oncol 20034167–176. - PubMed
    1. Lazcano‐Ponce E C, Miquel J F, Munoz N.et al Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 200151349–364. - PubMed
    1. LeRoith D, Roberts C T., Jr The insulin‐like growth factor system and cancer. Cancer Lett 200395127–137. - PubMed
    1. Pollak M N, Schernhammer E S, Hankinso S E. Insulin‐like growth factors and neoplasia. Nat Rev Cancer 20044505–518. - PubMed
    1. Foulstone E, Prince S, Zaccheo O.et al Insulin‐like growth factor ligands, receptors and binding proteins in cancer. J Pathol 2005205145–153. - PubMed

MeSH terms